Form 4: Celldex Therapeutics Grants 75,000 Stock Options to SVP & General Counsel

Celldex Therapeutics, Inc. has granted 75,000 incentive stock options to its SVP & General Counsel, Freddy A. Jimenez, under its 2021 Omnibus Equity Incentive Plan.

Summary

• Freddy A. Jimenez, the Senior Vice President and General Counsel of Celldex Therapeutics, Inc. (CLDX), was granted 75,000 incentive stock options.
• The options have an exercise price of $19.53 per share.
• The grant date for these options was June 5, 2025.
• The options were issued pursuant to the company's 2021 Omnibus Equity Incentive Plan.
• Vesting for the options begins on June 5, 2026, with 25% vesting on that date, and the remaining portion vesting quarterly in equal amounts over the subsequent 12 quarters.
• The expiration date for these options is June 5, 2035.
• Following this transaction, Freddy A. Jimenez beneficially owns 75,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The filing reports a routine grant of incentive stock options to a key executive, which is a standard compensation practice aimed at retention and aligning interests, thus indicating a neutral to slightly positive sentiment regarding corporate governance and executive alignment.

Positives

• The granting of incentive stock options aligns the interests of the SVP & General Counsel with shareholders, incentivizing long-term performance and value creation.
• The options are part of the company's 2021 Omnibus Equity Incentive Plan, indicating a structured and approved approach to executive compensation and retention.

Negatives

• NA

Risks

• NA

Future Outlook

The multi-year vesting schedule for the granted options, extending over three years, suggests a long-term retention strategy for a key executive, aligning their incentives with the company's sustained future performance and growth.

Management Comments

• NA

Industry Context

The granting of incentive stock options is a common and standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This mechanism aligns their long-term interests with the company's strategic objectives, research and development milestones, and overall shareholder value creation, which is typical for companies in this sector.

Comparison to Industry Standards

• The use of incentive stock options with a multi-year vesting schedule is a standard compensation practice across publicly traded companies, particularly in high-growth sectors like biotechnology, to ensure executive retention and performance alignment.
• While the specific number of options and exercise price are unique to this grant, the structure is consistent with typical executive compensation packages observed in comparable biotech firms, aiming to incentivize long-term commitment and performance.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• The grant of 75,000 incentive stock options to Freddy A. Jimenez, the SVP & General Counsel, constitutes a transaction with a related party (an officer of the company) as part of his compensation package.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the interests of the SVP & General Counsel with shareholders by incentivizing long-term company performance and share price appreciation.
• Employees: This specific filing does not directly impact other employees, but it reflects the company's executive compensation strategy and commitment to retaining key talent.

Next Steps

• The granted options will vest over a period, with 25% vesting on June 5, 2026, and the remainder vesting quarterly over the subsequent 12 quarters, subject to the executive's continued employment.

Key Dates

Recommendation

Keywords

Celldex Therapeutics, CLDX, stock options, incentive stock option, executive compensation, insider transaction, Form 4, equity incentive plan, Freddy A. Jimenez